Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar 21:9:9-18.
doi: 10.2147/DHPS.S121733. eCollection 2017.

Update on the usage and safety of epinephrine auto-injectors, 2017

Larry S Posner  1 , Carlos A Camargo Jr  2
Affiliations
Review

Update on the usage and safety of epinephrine auto-injectors, 2017

Larry S Posner et al. Drug Healthc Patient Saf. .

Abstract

Anaphylaxis is a serious, potentially fatal allergic reaction. Guidelines recommend prompt intramuscular injections of epinephrine as the first-line therapy for anaphylaxis. Delayed epinephrine treatment may cause undesirable clinical outcomes, including death. In the community, epinephrine auto-injectors (EAIs) are commonly used to treat anaphylaxis. This literature review examines several recent concerns regarding the safety of EAIs that may prevent the timely administration of epinephrine. Reports of cardiovascular complications are linked with epinephrine administration, although recent studies suggest that these events are much more commonly associated with intravenous epinephrine rather than with EAIs. Recent studies have also highlighted accidental injections of EAIs in patients' or caregivers' fingers and lacerations associated with the use of EAI in children. However, the data suggest that both accidental injections and lacerations are rare and require limited medical intervention. In addition, patients may receive conflicting information on the safety and efficacy of using expired EAIs. Overall, it is believed that the benefits of using EAIs far outweigh the potential risks of not administering an EAI. Although legitimate safety concerns are associated with EAIs, adverse events are rare. Continued training of medical providers, caregivers, and patients may be beneficial to address these concerns and reduce EAI-associated injuries while ensuring that patients receive necessary medical care.

Keywords: allergy; anaphylaxis; asthma; pediatrics.

PubMed Disclaimer

Conflict of interest statement

Disclosure Dr Posner has served on the scientific advisory board for Mylan Specialty L.P. and Dr Camargo for Mylan Specialty L.P. and Sanofi-Aventis. Dr Posner and Dr Camargo performed investigator-initiated research funded by Mylan Specialty L.P. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Criteria that increase the likelihood of anaphylaxis. Note: Adapted from Simons FE, Ardusso LR, Bilò MB, et al. World allergy organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J. 2011;4(2):13–37.
Figure 2
Figure 2
Pharmacological effects of epinephrine in the treatment of anaphylaxis.
Figure 3
Figure 3
Self-administration of an epinephrine auto-injector.
Figure 4
Figure 4
Comparison of the (A) old-look and (B) new-look (right) EpiPen® Auto-Injector (Mylan Specialty L.P., Canonsburg, PA, USA). Note: The EpiPen Auto-Injector was redesigned in 2011 to include safety features such as the orange needle sheath.
Figure 5
Figure 5
Proposed child restraint options for the administration of an epinephrine auto-injector. Note: Reprinted from The Journal of Allergy and Clinical Immunology: In Practice, Volume 4/edition 3, Brown JC, Tuuri RE, Lacerations and embedded needles due to EpiPen use in children, Pages 549–551, Copyright 2016, with permission from Elsevier and Julie Brown, MD, MPH.
See this image and copyright information in PMC

References

    1. Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report–second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med. 2006;47(4):373–380. - PubMed
    1. Simons FE, Ardusso LR, Bilò MB, et al. World allergy organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J. 2011;4(2):13–37. - PMC - PubMed
    1. Muraro A, Roberts G, Worm M, et al. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy. 2014;69(8):1026–1045. - PubMed
    1. Soar J, Pumphrey R, Cant A, et al. Emergency treatment of anaphylactic reactions – guidelines for healthcare providers. Resuscitation. 2008;77(2):157–169. - PubMed
    1. NIAID-Sponsored Expert Panel. Boyce JA, Assa’ad A, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol. 2010;126(6 Suppl):S1–S58. - PMC - PubMed

LinkOut - more resources